CPT code 82525 represents a laboratory assay for quantifying copper in a patient specimen, used primarily to investigate hepatocellular degeneration and obstructive liver disease. This test has clinical importance for diagnosing and monitoring disorders of copper metabolism and liver dysfunction; its accurate measurement can influence diagnosis and downstream clinical management.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national-level context for the code, including clinical indications, typical service settings, and the type of laboratory service represented. The publication outlines expected benchmarks where available, summarizes common billing considerations, and situates the test within clinical workflows for liver-related evaluations.

This summary provides clinicians, billing professionals, and policy analysts with a concise overview of the purpose and setting for CPT code 82525, what stakeholders commonly consider when processing claims for copper testing, and what to expect in terms of service categorization and clinical rationale. Data not available in the input: specific payer coverage policies, reimbursement rates, associated ICD-10 codes, and procedure modifiers.